vs
Healthpeak Properties（DOC）与Medpace Holdings, Inc.（MEDP）财务数据对比。点击上方公司名可切换其他公司
Healthpeak Properties的季度营收约是Medpace Holdings, Inc.的1.0倍（$719.4M vs $708.5M），Healthpeak Properties净利率更高（73.2% vs 19.1%，领先54.1%），Medpace Holdings, Inc.同比增速更快（32.0% vs 3.1%），Healthpeak Properties自由现金流更多（$357.0M vs $188.1M），过去两年Medpace Holdings, Inc.的营收复合增速更高（17.7% vs 8.9%）
Healthpeak Properties是美国医疗地产领域的房地产投资信托基金，核心投资范畴覆盖老年住宅、生命科学相关物业及医疗办公楼三类资产。公司2007年于马里兰州组建，总部设在科罗拉多州丹佛市，在尔湾、纳什维尔、旧金山均设有办事处，截至2019年12月31日共持有617处物业的权益。
Medpace Holdings, Inc.是总部位于美国俄亥俄州辛辛那提的全球性临床研究机构（CRO），现有员工约6000人。公司采用全服务运营模式，可提供全球中心实验室、影像核心实验室、生物分析实验室服务，且在总部临床研究园区内设有I期临床试验单元。
DOC vs MEDP — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $719.4M | $708.5M |
| 净利润 | $114.0M | $135.1M |
| 毛利率 | — | — |
| 营业利润率 | 17.4% | 21.6% |
| 净利率 | 73.2% | 19.1% |
| 营收同比 | 3.1% | 32.0% |
| 净利润同比 | 2406.4% | 15.5% |
| 每股收益（稀释后） | $0.16 | $4.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $719.4M | $708.5M | ||
| Q3 25 | $705.9M | $659.9M | ||
| Q2 25 | $694.3M | $603.3M | ||
| Q1 25 | $702.9M | $558.6M | ||
| Q4 24 | $698.0M | $536.6M | ||
| Q3 24 | $700.4M | $533.3M | ||
| Q2 24 | $695.5M | $528.1M | ||
| Q1 24 | $606.6M | $511.0M |
| Q4 25 | $114.0M | $135.1M | ||
| Q3 25 | $-117.1M | $111.1M | ||
| Q2 25 | $31.7M | $90.3M | ||
| Q1 25 | $42.8M | $114.6M | ||
| Q4 24 | $4.5M | $117.0M | ||
| Q3 24 | $85.9M | $96.4M | ||
| Q2 24 | $146.0M | $88.4M | ||
| Q1 24 | $6.7M | $102.6M |
| Q4 25 | — | — | ||
| Q3 25 | 58.6% | — | ||
| Q2 25 | 60.2% | — | ||
| Q1 25 | 61.1% | — | ||
| Q4 24 | 60.3% | — | ||
| Q3 24 | 60.0% | — | ||
| Q2 24 | 60.6% | — | ||
| Q1 24 | 59.8% | — |
| Q4 25 | 17.4% | 21.6% | ||
| Q3 25 | 9.2% | 21.5% | ||
| Q2 25 | 5.7% | 20.9% | ||
| Q1 25 | 7.7% | 20.3% | ||
| Q4 24 | -2.2% | 23.4% | ||
| Q3 24 | 14.1% | 21.1% | ||
| Q2 24 | 22.3% | 19.9% | ||
| Q1 24 | 3.7% | 20.4% |
| Q4 25 | 73.2% | 19.1% | ||
| Q3 25 | -16.6% | 16.8% | ||
| Q2 25 | 4.6% | 15.0% | ||
| Q1 25 | 6.1% | 20.5% | ||
| Q4 24 | 0.7% | 21.8% | ||
| Q3 24 | 12.3% | 18.1% | ||
| Q2 24 | 21.0% | 16.7% | ||
| Q1 24 | 1.1% | 20.1% |
| Q4 25 | $0.16 | $4.65 | ||
| Q3 25 | $-0.17 | $3.86 | ||
| Q2 25 | $0.05 | $3.10 | ||
| Q1 25 | $0.06 | $3.67 | ||
| Q4 24 | $0.02 | $3.67 | ||
| Q3 24 | $0.12 | $3.01 | ||
| Q2 24 | $0.21 | $2.75 | ||
| Q1 24 | $0.01 | $3.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $467.5M | $497.0M |
| 总债务越低越好 | $9.8B | — |
| 股东权益账面价值 | $7.5B | $459.1M |
| 总资产 | $20.3B | $2.0B |
| 负债/权益比越低杠杆越低 | 1.31× | — |
8季度趋势，按日历期对齐
| Q4 25 | $467.5M | $497.0M | ||
| Q3 25 | $91.0M | $285.4M | ||
| Q2 25 | $89.4M | $46.3M | ||
| Q1 25 | $70.6M | $441.4M | ||
| Q4 24 | $119.8M | $669.4M | ||
| Q3 24 | $180.4M | $656.9M | ||
| Q2 24 | $106.9M | $510.9M | ||
| Q1 24 | $101.8M | $407.0M |
| Q4 25 | $9.8B | — | ||
| Q3 25 | $9.1B | — | ||
| Q2 25 | $9.0B | — | ||
| Q1 25 | $8.9B | — | ||
| Q4 24 | $8.7B | — | ||
| Q3 24 | $8.6B | — | ||
| Q2 24 | $8.6B | — | ||
| Q1 24 | $8.8B | — |
| Q4 25 | $7.5B | $459.1M | ||
| Q3 25 | $7.6B | $293.6M | ||
| Q2 25 | $7.9B | $172.4M | ||
| Q1 25 | $8.2B | $593.6M | ||
| Q4 24 | $8.4B | $825.5M | ||
| Q3 24 | $8.6B | $881.4M | ||
| Q2 24 | $8.8B | $763.6M | ||
| Q1 24 | $8.9B | $671.5M |
| Q4 25 | $20.3B | $2.0B | ||
| Q3 25 | $19.6B | $1.8B | ||
| Q2 25 | $19.8B | $1.6B | ||
| Q1 25 | $19.8B | $1.9B | ||
| Q4 24 | $19.9B | $2.1B | ||
| Q3 24 | $20.0B | $2.1B | ||
| Q2 24 | $20.2B | $1.9B | ||
| Q1 24 | $20.5B | $1.8B |
| Q4 25 | 1.31× | — | ||
| Q3 25 | 1.20× | — | ||
| Q2 25 | 1.14× | — | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 1.04× | — | ||
| Q3 24 | 1.00× | — | ||
| Q2 24 | 0.98× | — | ||
| Q1 24 | 0.99× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.3B | $192.7M |
| 自由现金流经营现金流 - 资本支出 | $357.0M | $188.1M |
| 自由现金流率自由现金流/营收 | 49.6% | 26.6% |
| 资本支出强度资本支出/营收 | 124.4% | 0.6% |
| 现金转化率经营现金流/净利润 | 10.99× | 1.43× |
| 过去12个月自由现金流最近4个季度 | — | $681.9M |
8季度趋势，按日历期对齐
| Q4 25 | $1.3B | $192.7M | ||
| Q3 25 | $315.0M | $246.2M | ||
| Q2 25 | $363.5M | $148.5M | ||
| Q1 25 | $279.4M | $125.8M | ||
| Q4 24 | $1.1B | $190.7M | ||
| Q3 24 | $318.2M | $149.1M | ||
| Q2 24 | $316.2M | $116.4M | ||
| Q1 24 | $152.6M | $152.7M |
| Q4 25 | $357.0M | $188.1M | ||
| Q3 25 | — | $235.5M | ||
| Q2 25 | — | $142.4M | ||
| Q1 25 | — | $115.8M | ||
| Q4 24 | $333.7M | $183.0M | ||
| Q3 24 | — | $138.5M | ||
| Q2 24 | — | $103.5M | ||
| Q1 24 | — | $147.2M |
| Q4 25 | 49.6% | 26.6% | ||
| Q3 25 | — | 35.7% | ||
| Q2 25 | — | 23.6% | ||
| Q1 25 | — | 20.7% | ||
| Q4 24 | 47.8% | 34.1% | ||
| Q3 24 | — | 26.0% | ||
| Q2 24 | — | 19.6% | ||
| Q1 24 | — | 28.8% |
| Q4 25 | 124.4% | 0.6% | ||
| Q3 25 | — | 1.6% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 1.8% | ||
| Q4 24 | 105.6% | 1.4% | ||
| Q3 24 | — | 2.0% | ||
| Q2 24 | — | 2.4% | ||
| Q1 24 | — | 1.1% |
| Q4 25 | 10.99× | 1.43× | ||
| Q3 25 | — | 2.22× | ||
| Q2 25 | 11.48× | 1.65× | ||
| Q1 25 | 6.52× | 1.10× | ||
| Q4 24 | 235.43× | 1.63× | ||
| Q3 24 | 3.71× | 1.55× | ||
| Q2 24 | 2.17× | 1.32× | ||
| Q1 24 | 22.85× | 1.49× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOC
暂无分部数据
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
